Disease frequency and characteristics of patients with systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Qiang Li,¹ Laura Wallace,² Padmaja Patnaik,² Margarida Alves,³ Martina Gahlemann,⁴ Veronika Kohlbrenner,² Christina Raabe,³ Jocelyn R. Wang,⁵ Elizabeth M. Garry⁵

¹Boehringer Ingelheim (China) Investment Co. Ltd, Shanghai, China; ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; ³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; ⁵Aetion, Inc., Boston, MA, USA



- To estimate prevalence and incidence rates of SSc and SSc-ILD in the MarketScan[®] claims database
- To describe patient characteristics among incident cases of SSc and SSc-ILD in the MarketScan[®] claims database

STUDY DESIGN

US IBM[®] MarketScan[®] claims database (2008–17)


De-identified outpatient, inpatient and pharmaceutical claims of privately insured patients Descriptive analyses performed using Aetion Evidence Platform[™] (v3.12)

Prevalence: number of incident and existing cases divided by number of patients at risk **Incidence rate:** number of incident cases divided by person-years at risk

Patients aged \geq 18 years with ≥365 days' continuous enrolment



≥1 diagnostic claim for SSc, 2009–17¹



¹Primary analysis required ≥ 1 claim for SSc; for SSc-ILD, ≥ 1 claim for SSc plus ≥ 2 claims for SSc; for SSc-ILD, ≥ 2 claims for SSc; for SSc-ILD, ≥ 2 claims for ILD within 365 days prior, on or after the SSc claim was required.

RESULTS

ESTIMATED PREVALENCE AND INCIDENCE RATE OF SSc AND SSc-ILD BETWEEN 2009 AND 2017

Total patients at risk: 78,964,708

P	PRIMARY ANALYSIS (≥1 claim for SSc or SSc+ILD)				SENSITIVITY ANALYSIS (≥2 claims for SSc or SSc+IL				c or SSc+ILD)
	Number of new and existing cases	PREVALENCE per 100,000 persons	Number of new cases	INCIDENCE per 100,000 person-years		Number of new and existing cases	PREVALENCE per 100,000 persons	Number of new cases	INCIDENCE per 100,000 person-years
SSc	56,923	72.1	34,820	18.3	SSc	32,732	41.5	16,820	8.8
SSc-ILD	15,005	19.0	8,252	4.3	SSc-ILI	D 7,767	9.8	3,120	1.6

- >80% of patients with SSc and SSc-ILD were female
- Prevalence and incidence rates of SSc and SSc-ILD were both higher in females compared with males



- Estimates of prevalence and incidence rates for both SSc and SSc-ILD were higher compared with other similar studies^{1,2}
- The high prevalence and incidence rate of SSc in this large database analysis may be attributed to the methodology and was reduced when using ≥ 2 claims for diagnosis

BASELINE PATIENT CHARACTERISTICS AND DIAGNOSTIC PROCEDURES FOR INCIDENT SSc AND SSc-ILD (primary analysis)



∇		SSc (n=34,820)	SSc-ILD (n=8,252)
	Mean age, years (SD)	53.6 (14.48)	58.3 (13.46)
<text></text>	Sex, n (%)		
	Female	29,141 (83.7)	6,750 (81.8)
	Diagnostic procedures at baseline, n (%)		
	Regular lab tests	28,130 (80.8)	6,946 (84.2)
	Auto-antibodies	12,598 (36.2)	3,328 (40.3)
	Chest X-ray	12,147 (34.9)	5,296 (64.2)
	Spirometry	5,282 (15.2)	3,623 (43.9)
	Pulmonary function test	5,256 (15.1)	3,625 (43.9)
	Abdomen ultrasound	4,229 (12.1)	1,435 (17.4)
	Chest CT	4,678 (13.4)	3,658 (44.3)
	HRCT	2,588 (7.4)	2,465 (29.9)
More diagnostic procedures for patients with SSc-ILD than SSc	Lung volumes	1,619 (4.6)	1,450 (17.6)
	Heart ultrasound	1,765 (5.1)	776 (9.4)
	Six-minute walking test	834 (2.4)	767 (9.3)

PREVALENCE OF COMORBIDITIES AT BASELINE AMONGST PATIENTS WITH SSc **AND SSc-ILD**

	Comorbidity, % (95% CI)	SSc (n=34,820)	SSc-ILD (n=8,252)
	Skin disorders	28.8 (28.3, 29.3)	34.5 (33.4, 35.5)
Higher rates of comorbidities	Gastroesophageal reflux	17.9 (17.5, 18.3)	28.5 (27.5, 29.4)
in SSc-ILD	Upper respiratory tract infections	11.1 (10.8, 11.5)	11.3 (10.6, 12.0)
versus SSc, including skin	Type 2 diabetes mellitus	10.2 (9.8, 10.5)	13.2 (12.5, 13.9)
disorders, gastro-	Raynaud syndrome	7.8 (7.5, 8.1)	14.5 (13.8, 15.3)
esophageal reflux, COPD,	COPD	7.6 (7.3, 7.9)	20.7 (19.8, 21.5)
pneumonia and Raynaud syndrome	Chronic and acute renal failure or insufficiency	6.7 (6.4, 6.9)	12.2 (11.5, 12.9)
Syndiome	Cardiac arrhythmia	6.5 (6.3, 6.8)	12.3 (11.6, 13.0)
	Arterial hypertension	6.3 (6.0, 6.5)	13.8 (13.1, 14.6)
	Urinary tract infections	6.3 (6.0, 6.5)	8.7 (8.1, 9.4)
	Pneumonia	3.3 (3.1, 3.5)	11.4 (10.7, 12.1)
Skin disorders were the	Pulmonary hypertension	3.2 (3.0, 3.4)	11.2 (10.6, 11.9)
most frequent comorbidity	Acute respiratory failure	1.5 (1.3, 1.6)	5.1 (4.6, 5.6)
in both SSc and SSc-ILD	Pulmonary arterial hypertension	0.1 (0.1, 0.2)	0.5 (0.3, 0.6)

CONCLUSIONS

- Demographic characteristics were consistent with previously published literature^{1,3}
- In this large database analysis, patients with SSc-ILD had a higher burden of disease (in terms of comorbidities) and higher healthcare resource use (in terms of diagnostic procedures) compared with patients with SSc
 - The higher burden of disease for patients with SSc-ILD may be related to these patients having other internal organ involvement and having had this disease for a longer period



References

1. Bergamasco A, et al. Clin Epidemiol 2019; 11:257–273; 2. Fan Y, et al. J Manag Care Spec Pharm 2018; 24(10-a Suppl):S71;

3. Distler O, et al. New Engl J Med 2019; 380:2518–2528.



Abbreviations

CI, confidence interval; COPD, chronic obstructive pulmonary disease; CT, computed tomography; HRCT, high-resolution CT; ILD, interstitial lung disease; SD, standard deviation; SSc, systemic sclerosis.

Disclosures

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of the poster. Medical writing, editorial support and formatting assistance was provided by Helen Keyworth, PhD, of Nucleus Global, which was contracted and funded by Boehringer Ingelheim International GmbH (BI). BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.

Relationships and activities

QL is an employee of Boehringer Ingelheim (China) Investment Co., Ltd. LW, PP and VK are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MA and CR are employees of Boehringer Ingelheim International GmbH. MG is an employee of Boehringer Ingelheim (Schweiz) GmbH. JRW and EMG are full-time employees of Action, Inc. with stock options; Action was contracted by Boehringer Ingelheim International GmbH and authorship of this poster was performed in kind.

